- Home
- LWAC vs RCKT Comparison
LWAC vs RCKT Comparison
Compare LWAC & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
HOLD
Current Price
$3.45
Company Overview
Basic Information| Metric | LWAC | RCKT |
|---|---|---|
| Founded | 2025 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 301.7M | 340.9M |
| IPO Year | 2025 | N/A |
Fundamental Metrics
Financial Performance| Metric | LWAC | RCKT |
|---|---|---|
| Price | $10.03 | $3.45 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 14 |
| Target Price | N/A | ★ $29.12 |
| AVG Volume (30 Days) | 33.1K | ★ 1.9M |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.81 | $2.19 |
| 52 Week High | $10.12 | $13.35 |
Technical Indicators
Market Signals| Indicator | LWAC | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 51.89 |
| Support Level | N/A | $3.36 |
| Resistance Level | N/A | $3.64 |
| Average True Range (ATR) | 0.00 | 0.18 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 0.00 | 56.18 |
Price Performance
Historical Comparison LWAC
RCKT
About LWAC LightWave Acquisition Corp. Class A Ordinary Shares
LightWave Acquisition Corp is a blank check company.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.